Magnitude of Enhanced Permeability and Retention Effect in Tumors with Different Phenotypes: 89Zr-albumin As a Model System

Overview

Journal J Nucl Med

Specialty Nuclear Medicine

Date 2011 Mar 23

PMID 21421727

Citations 81

Authors

Carola Heneweer

Jason P Holland

Vadim Divilov

Sean Carlin

Jason S Lewis

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Targeted nanoparticle-based technologies show increasing prevalence in radiotracer design. As a consequence, quantitative contribution of nonspecific accumulation in the target tissue, mainly governed by the enhanced permeability and retention (EPR) effect, becomes highly relevant for evaluating the specificity of these new agents. This study investigated the influence of different tumor phenotypes on the EPR effect, hypothesizing that a baseline level of uptake must be exceeded to visualize high and specific uptake of a targeted macromolecular radiotracer.

Methods: These preliminary studies use (89)Zr-labeled mouse serum albumin ((89)Zr-desferrioxamine-mAlb) as a model radiotracer to assess uptake and retention in 3 xenograft models of human prostate cancer (CWR22rv1, DU-145, and PC-3). Experiments include PET and contrast-enhanced ultrasound imaging to assess morphology, vascularization, and radiotracer uptake; temporal ex vivo biodistribution studies to quantify radiotracer uptake over time; and histologic and autoradiographic studies to evaluate the intra- and intertumoral distribution of (89)Zr-desferrioxamine-mAlb.

Results: Early uptake profiles show statistically significant but overall small differences in radiotracer uptake between different tumor phenotypes. By 20 h, nonspecific radiotracer uptake was found to be independent of tumor size and phenotype, reaching at least 5.0 percentage injected dose per gram in all 3 tumor models.

Conclusion: These studies suggest that minimal differences in tumor uptake exist at early time points, dependent on the tumor type. However, these differences equalize over time, reaching around 5.0 percentage injected dose per gram at 20 h after injection. These data provide strong support for the introduction of mandatory experimental controls of future macromolecular or nanoparticle-based drugs, particularly regarding the development of targeted radiotracers.

Citing Articles

Assessing Therapeutic Nanoparticle Accumulation in Tumors Using Nanobubble-Based Contrast-Enhanced Ultrasound Imaging.

Cooley M, Wegierak D, Perera R, Abenojar E, Nittayacharn P, Berg F ACS Nano. 2024; 18(48):33181-33196.

PMID: 39566912 PMC: 11619768. DOI: 10.1021/acsnano.4c11805.

Immuno-PET Imaging of EGFR with Cu-NOTA Panitumumab in Subcutaneous and Metastatic Nonsmall Cell Lung Cancer Xenografts.

Sarrami N, Wuest M, Paiva I, Leier S, Lavasanifar A, Wuest F Mol Pharm. 2024; 21(11):5797-5806.

PMID: 39402973 PMC: 11539060. DOI: 10.1021/acs.molpharmaceut.4c00823.

PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer.

Meher N, Bidkar A, Wadhwa A, Bobba K, Dhrona S, Dasari C Mol Cancer Ther. 2024; 24(1):141-151.

PMID: 39331510 PMC: 11694059. DOI: 10.1158/1535-7163.MCT-24-0024.

Comparison of Tumor Non-specific and PD-L1 Specific Imaging by Near-Infrared Fluorescence/Cerenkov Luminescence Dual-Modality In-situ Imaging.

Zhang L, Zhao L, Lin X, Zhao S, Pan W, Wang D Mol Imaging. 2024; 23:15353508241261473.

PMID: 38952401 PMC: 11208884. DOI: 10.1177/15353508241261473.

Phase 2 Clinical Trial of VGT-309 for Intraoperative Molecular Imaging During Pulmonary Resection.

Bou-Samra P, Kennedy G, Chang A, Guo E, Azari F, Din A Ann Thorac Surg. 2024; 119(3):625-633.

PMID: 38823756 PMC: 11607179. DOI: 10.1016/j.athoracsur.2024.05.019.

References

Holland J, Caldas-Lopes E, Divilov V, Longo V, Taldone T, Zatorska D . Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PLoS One. 2010; 5(1):e8859. PMC: 2810330. DOI: 10.1371/journal.pone.0008859. View

Maeda H . SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev. 2001; 46(1-3):169-85. DOI: 10.1016/s0169-409x(00)00134-4. View

Matsumura Y, Maeda H . A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46(12 Pt 1):6387-92. View

Niu Y, Yeh S, Miyamoto H, Li G, Altuwaijri S, Yuan J . Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res. 2008; 68(17):7110-9. PMC: 2587124. DOI: 10.1158/0008-5472.CAN-07-6507. View

Holland J, Sheh Y, Lewis J . Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol. 2009; 36(7):729-39. PMC: 2827875. DOI: 10.1016/j.nucmedbio.2009.05.007. View

Maeda H, Seymour L, Miyamoto Y . Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug Chem. 1992; 3(5):351-62. DOI: 10.1021/bc00017a001. View

Brown J, Wilson W . Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004; 4(6):437-47. DOI: 10.1038/nrc1367. View

Maeda H . Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem. 2010; 21(5):797-802. DOI: 10.1021/bc100070g. View

Maeda H, Sawa T, Konno T . Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release. 2001; 74(1-3):47-61. DOI: 10.1016/s0168-3659(01)00309-1. View

10.

Pienta K, Abate-Shen C, Agus D, Attar R, Chung L, Greenberg N . The current state of preclinical prostate cancer animal models. Prostate. 2008; 68(6):629-39. PMC: 3681409. DOI: 10.1002/pros.20726. View

11.

Wei K, Jayaweera A, Firoozan S, Linka A, Skyba D, Kaul S . Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation. 1998; 97(5):473-83. DOI: 10.1161/01.cir.97.5.473. View

12.

Kim J, Bronson C, Hayton W, Radmacher M, Roopenian D, Robinson J . Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol Gastrointest Liver Physiol. 2005; 290(2):G352-60. DOI: 10.1152/ajpgi.00286.2005. View

13.

Holland J, Divilov V, Bander N, Smith-Jones P, Larson S, Lewis J . 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010; 51(8):1293-300. PMC: 2998794. DOI: 10.2967/jnumed.110.076174. View

14.

Torchilin V . Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2010; 63(3):131-5. DOI: 10.1016/j.addr.2010.03.011. View

15.

Zalipsky S, Saad M, Kiwan R, Ber E, Yu N, Minko T . Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: insights of the mechanism of action. J Drug Target. 2007; 15(7-8):518-30. DOI: 10.1080/10611860701499946. View

16.

Anderson C, Schwarz S, Connett J, Cutler P, Guo L, Germain C . Preparation, biodistribution and dosimetry of copper-64-labeled anti-colorectal carcinoma monoclonal antibody fragments 1A3-F(ab')2. J Nucl Med. 1995; 36(5):850-8. View

17.

Burger A, Hartung G, Stehle G, Sinn H, Fiebig H . Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo. Int J Cancer. 2001; 92(5):718-24. DOI: 10.1002/1097-0215(20010601)92:5<718::aid-ijc1257>3.0.co;2-d. View

18.

Brown J . The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 1999; 59(23):5863-70. View

19.

Levick J . Permeability of rheumatoid and normal human synovium to specific plasma proteins. Arthritis Rheum. 1981; 24(12):1550-60. DOI: 10.1002/art.1780241215. View

20.

Stehle G, Sinn H, Wunder A, Schrenk H, Stewart J, Hartung G . Plasma protein (albumin) catabolism by the tumor itself--implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol. 1997; 26(2):77-100. DOI: 10.1016/s1040-8428(97)00015-2. View